Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.